MAPT and Alzheimer disease: Furthermore, Tideglusib, as a non‐ATP‐competitive GSK3β inhibitor, reduced Tau phosphorylation levels, decreased Aβ deposition and astrocyte proliferation, and improved memory performance in the AD mouse model (Sereno et al., 2009; Wang et al., 2016).